Incyte· @Incyte · X·· 2026-05-30AI 评分20
AI 导读
了解执行副总裁、首席医学官兼晚期开发负责人 Steven Stein 医学博士的更多分享，他讨论了 III 期 frontMIND 数据对既往未经治疗的弥漫性大 B 细胞淋巴瘤（DLBCL）患者的意义，这些数据在今年的 @ASCO 会议上公布。https://bit.ly/4vc6uhc
正文
Learn more from Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-stage Development, as he discusses the significance of the Phase 3 frontMIND data for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), shared at this year’s @ASCO Meeting. https://bit.ly/4vc6uhc
来源：Incyte · x.com